A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

医学 卡奇霉素 内科学 微小残留病 耐火材料(行星科学) Blinatumoab公司 累积发病率 造血干细胞移植 细胞因子释放综合征 胃肠病学 移植 肿瘤科 白血病 癌症 嵌合抗原受体 淋巴细胞白血病 免疫疗法 髓系白血病 物理 天体生物学
作者
Maureen M. O'Brien,Lingyun Ji,Nirali N. Shah,Susan R. Rheingold,Deepa Bhojwani,Joanna S. Yi,Constance M. Yuan,Andrew C. Harris,Patrick A. Brown,Michael J. Borowitz,Olga Militano,Meenakshi Devidas,Elizabeth A. Raetz,Lia Gore,Mignon L. Loh
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 741-741 被引量:29
标识
DOI:10.1182/blood-2019-128977
摘要

Background: Approximately 10-20% of children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) will relapse. Therapies that can bridge patients (pts) to hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR)-T cell therapy are critical to improving outcomes. Inotuzumab ozogamicin (InO) is a CD22-targeted antibody-drug conjugate linked to calicheamicin that is FDA-approved for adults with R/R refractory B-ALL. Prospective data on the efficacy and safety of InO in pediatric pts is lacking. Methods: This single arm phase 2 trial enrolled pts age 1-21 years with CD22-positive B-ALL in >2nd relapse, refractory to 2 prior induction regimens, any relapse after HSCT, or 1st relapse with Down syndrome (DS). The primary aim was rate of complete response (CR) or CR with incomplete count recovery (CRi) following cycle 1. Secondary aims included adverse events, incidence of sinusoidal obstruction syndrome (SOS), and level of minimal residual disease (MRD) measured by multiparameter flow cytometry in responders. Eligibility included ≥5% marrow blasts, direct bilirubin ≤1.5x upper limit of normal, and no prior SOS. Pts received one cycle of InO at the FDA-approved adult dose of 1.8mg/m2 (0.8mg/m2 on day 1, 0.5mg/m2 on days 8 and 15). Central nervous system (CNS) status dictated intrathecal therapy. Based on response at day 28, pts with at least stable disease (SD) could receive a 2nd cycle; those with CR/CRi received InO 0.5mg/m2 on days 1, 8, and 15 in cycle 2, while those without CR/CRi received the same fractionated dose as cycle 1. Pts with CR/CRi after 2 cycles were eligible to receive up to 6 total cycles. The trial used an admissible two-stage design (α=0.05, β=0.20) testing the null hypothesis of CR/CRi rate of 30% vs. alternative of 48%, requiring a minimum of 9/24 (response/enrolled) for stage 1 and 20/48 total. The trial was continuously monitored for dose-limiting toxicities (DLT) and SOS. Results herein are based on data cutoff of June 30, 2019. Results: Forty-eight pts received InO and were evaluable for response/toxicity. Median age was 9 years (range 1-21). Three pts had DS. 67% were in >2nd relapse, 21% were in 1st relapse but refractory to reinduction, 23% had prior HSCT, 23% had prior CD19 CAR-T, and 29% had prior blinatumomab. Median marrow blasts were 81% (range 6-100), with 81% of pts having M3 marrow. 19 pts achieved CR and 9 achieved CRi after cycle 1 (CR/CRi rate: 58.3%, 95%CI 43.2-72.4%). Three pts had partial response (PR), 9 SD, and 8 progressive disease (PD); 2 pts (1 PR, 1 SD) had CR/CRi with cycle 2. Two pts with PD in cycle 1 had marrow CR (MRD 0.02% and <0.01% in 1 case each) but progression in the CNS. MRD was reported for 26 of the 28 pts with CR/CRi; of these, 17 (65.4%) had MRD <0.01% and 4 (15.4%) had MRD 0.01-0.099%. The most common adverse events (AE) in cycle 1 were febrile neutropenia (27%) and infection (18.8%). No treatment related toxic deaths were reported. DLTs were reported in 9 pts in cycle 1; the most common DLT was hematologic [absolute neutrophils <500/µL or platelets <20,000/µL beyond 42 days from the start of cycle 1 (n = 7)], but DLT stopping bounds were not crossed. One pt was not evaluable for hematologic DLT. Four (8.3%) pts had ALT elevation, 6 (12.5%) had AST elevation (maximum grade 3), and 1 had grade 3 bilirubin in cycle 1. No pt required dose modification for hepatic toxicity. Thirteen pts had subsequent HCST and 4 (30.7%) developed SOS. All SOS cases were grade 3 (CTCAE v 5.0) and treated with defibrotide; 3 resolved quickly while one was more severe but resolving at the time of death from other HSCT complications. There were no cases of SOS without subsequent HSCT. Limited samples showed that alteration in surface CD22 expression is a likely mechanism for non-response. Peripheral B cell aplasia was nearly universal in evaluated pts. Conclusions: InO demonstrated a CR/CRi rate of 58% in these heavily pretreated children and young adults with R/R CD22-positive B-ALL. In responders, 65.4% achieved MRD <0.01%. Minimal hepatic toxicity was observed during InO therapy. SOS occurred in 30.7% of pts who underwent subsequent HSCT (8.3% of pts overall), and all but 1 case resolved quickly with supportive care and defibrotide. The most common DLT was prolonged marrow aplasia. Given the observed efficacy, InO will be incorporated into a randomized phase 3 trial for newly diagnosed pediatric pts with high-risk B-ALL. Disclosures O'Brien: Pfizer: Research Funding; Celgene: Research Funding; AbbVie: Research Funding; Amgen: Research Funding; BMS: Research Funding; BTG: Research Funding. Rheingold:Pfizer: Research Funding; Novartis: Consultancy. Borowitz:Beckman Coulter: Honoraria. Raetz:Pfizer: Research Funding. Gore:Amgen: Consultancy, Equity Ownership, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel expenses; Novartis: Consultancy, Other: Service on Data Safety Monitoring Committee; travel, accommodations, expenses; Roche/Genentech: Consultancy, Honoraria, Other: travel expenses; Anchiano: Equity Ownership, Other: spouse employment and company leadership; Blueprint Medicines: Equity Ownership; Celgene: Equity Ownership, Other: DSMC member; Clovis: Equity Ownership; Mirati: Equity Ownership; Sanofi Paris: Equity Ownership. Loh:Medisix Therapeutics, Inc.: Membership on an entity's Board of Directors or advisory committees. OffLabel Disclosure: Inotuzumab ozogamicin is FDA-approved for adults with relapsed B-ALL but is not approved for children. Its use in a pediatric population with relapsed B-ALL will be presented
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
4秒前
自由的鹏涛完成签到,获得积分20
7秒前
8秒前
在水一方应助Nayvue采纳,获得10
8秒前
11秒前
Ryan完成签到,获得积分10
12秒前
General完成签到 ,获得积分10
12秒前
谦让汝燕完成签到,获得积分10
14秒前
wellyou完成签到,获得积分10
15秒前
mint完成签到,获得积分10
17秒前
afli完成签到 ,获得积分0
20秒前
21秒前
Yy完成签到 ,获得积分10
24秒前
Nayvue发布了新的文献求助10
26秒前
feng完成签到,获得积分10
26秒前
淡淡的小蘑菇完成签到 ,获得积分10
29秒前
G_Serron完成签到,获得积分10
30秒前
swordshine完成签到,获得积分10
30秒前
Anonymous完成签到,获得积分10
34秒前
medzhou完成签到,获得积分10
38秒前
儒雅的千秋完成签到,获得积分10
46秒前
普鲁卡因发布了新的文献求助10
49秒前
小雯完成签到,获得积分10
50秒前
搞怪梦寒完成签到,获得积分20
51秒前
喵了个咪完成签到 ,获得积分10
52秒前
mc完成签到 ,获得积分10
54秒前
量子星尘发布了新的文献求助10
57秒前
58秒前
58秒前
虚幻谷波完成签到,获得积分10
1分钟前
ruochenzu发布了新的文献求助10
1分钟前
小马甲应助搞怪梦寒采纳,获得10
1分钟前
firewood完成签到 ,获得积分10
1分钟前
天天快乐应助普鲁卡因采纳,获得10
1分钟前
orixero应助NXK采纳,获得10
1分钟前
bjr完成签到 ,获得积分10
1分钟前
研友_LwlAgn完成签到,获得积分10
1分钟前
陈昊完成签到,获得积分10
1分钟前
1分钟前
tian发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022